<DOC>
	<DOCNO>NCT02965976</DOCNO>
	<brief_summary>This randomized phase II trial study well botulinum toxin type A work prevent complication surgery patient esophageal cancer . Botulinum toxin type A may cause less complication nausea vomit surgery .</brief_summary>
	<brief_title>Botulinum Toxin Type A Preventing Complications After Surgery Patients With Esophageal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine intra-pyloric botulinum toxin type A ( botulinum toxin ) injection ( Botox ) minimally invasive esophagectomy decrease postoperative occurrence delay gastric emptying . SECONDARY OBJECTIVES : I . Determine intra-pyloric botulinum toxin injection minimally invasive esophagectomy reduces number repeat procedure delay gastric empty within 90 day . II . Determine intra-pyloric botulinum toxin injection minimally invasive esophagectomy decrease time oral intake meeting 100 % nutritional requirement . III . Determine intra-pyloric botulinum toxin injection minimally invasive esophagectomy reduces incidence pulmonary complication directly relate delay gastric emptying . IV . Determine intra-pyloric botulinum toxin injection minimally invasive esophagectomy reduces hospital length stay relate delayed gastric empty . V. Determine intra-pyloric botulinum toxin injection minimally invasive esophagectomy increase patient quality life . OUTLINE : Patients randomize 1 2 arm . ARM I : Patients receive botulinum toxin type A injection intramuscularly ( IM ) undergo standard minimally invasive esophagectomy . ARM II : Patients undergo standard minimally invasive esophagectomy . After completion study treatment , patient follow 2 , 3-4 , 6-8 week , 90 day .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Esophageal carcinoma , undergo minimally invasive esophagectomy intrathoracic anastomosis Have Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Participant legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure Patients history gastrointestinal dysmotility functional gastroparesis , include diabetic gastroparesis , central peripheral nervous system disorder , renal failure , medication side effect , include chronic dependence promotility agent , anticholinergic antispasmodic agent , daily narcotic use Patients history previous gastric duodenal surgery Patients history duodenal ulcer duodenal fibrosis Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Allergy botulinum toxin Pregnant nursing female participant Unwilling unable follow protocol requirement Any condition investigator 's opinion deem participant unsuitable candidate study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>